Selected article for: "acute respiratory syndrome and lpv antiviral activity"
Author: Sandra De Meyer; Denisa Bojkova; Jindrich Cinati; Ellen Van Damme; Christophe Buyck; Marnix Van Loock; Brian Woodfall; Sandra Ciesek
Title: Lack of Antiviral Activity of Darunavir against SARS-CoV-2
  • Document date: 2020_4_8
    • ID: 679qfp2s_2
    Snippet: As no specific antivirals for treatment of COVID-19 are available, one avenue of clinical interest is the use of human immunodeficiency virus (HIV) protease inhibitors (PIs) as a therapeutic intervention. The potential for HIV PIs as a treatment for COVID-19 is mainly based on limited virologic and clinical data on the HIV protease inhibitor lopinavir with low-dose ritonavir (as a pharmacoenhancer; LPV/r) in patients infected with severe acute re.....
    Document: As no specific antivirals for treatment of COVID-19 are available, one avenue of clinical interest is the use of human immunodeficiency virus (HIV) protease inhibitors (PIs) as a therapeutic intervention. The potential for HIV PIs as a treatment for COVID-19 is mainly based on limited virologic and clinical data on the HIV protease inhibitor lopinavir with low-dose ritonavir (as a pharmacoenhancer; LPV/r) in patients infected with severe acute respiratory syndrome related to a coronavirus (SARS-CoV) (4) . After demonstrating the in vitro antiviral activity of LPV against SARS-CoV-1, the clinical response of patients with SARS to a combination of LPV/r and ribavirin was examined. Patients treated with LPV/r had lower rates of adverse clinical outcomes at day 21 following the onset of symptoms compared with historical controls (4). However, recent data in hospitalized adults with severe confirmed COVID-19 treated with LPV/r in addition to a standard care of ventilation, oxygen, vasopressor support, antibiotics and renalreplacement therapy showed that there was no significant improvement in time to clinical improvement or mortality at day 28 compared with the standard care (5).

    Search related documents:
    Co phrase search for related documents
    • adverse clinical outcome and clinical improvement: 1, 2, 3, 4, 5
    • adverse clinical outcome and clinical outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse clinical outcome and clinical response: 1, 2
    • adverse clinical outcome and historical control: 1
    • adverse clinical outcome and low dose: 1
    • antiviral activity and clinical improvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • antiviral activity and clinical interest: 1, 2
    • antiviral activity and clinical outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • antiviral activity and clinical response: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral activity and HIV protease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • antiviral activity and HIV protease inhibitor: 1, 2, 3, 4, 5, 6, 7
    • antiviral activity and hospitalized adult: 1, 2, 3
    • antiviral activity and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and human immunodeficiency virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and low dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • antiviral activity and low rate: 1, 2, 3, 4, 5
    • antiviral activity and LPV antiviral activity: 1, 2, 3
    • clinical improvement and low dose ritonavir: 1
    • clinical improvement and low rate: 1, 2, 3, 4, 5, 6, 7